With a historical investment performance in the top 1% of venture capital, Thynk Capital is a capital-efficient investment firm that focuses on companies with 100X return potential. Their primary focus is on extending life and addressing major diseases of aging, including Alzheimer's, Dementia, Kidney Disease, Cancer, Diabetes, and human frailty. Founded in 2003, the team is comprised of biotech entrepreneur investors with over 20 years of experience in the industry.